If you are having trouble reading this email, read the online version

Claim Your Share of the Potential $105 Billion Weight Management Market

The weight loss market is on the brink of unprecedented transformation. Morgan Stanley projects weight loss pharmaceutical sales to surge from $6 billion in 2023 to $105 billion by 2030, and GLP-1 drugs like Ozempic are leading this revolution. But where does that leave supplement brands? The opportunities are limitless—if you know how to position yourself.

NBJ's latest report, Supplements in the Ozempic Age, provides essential insights into the consumer journey across all stages of GLP-1 drug use, from non-users to current users and those who have discontinued. These findings reveal new opportunities for growth in the weight loss and blood sugar management markets.

With GLP-1 drugs’ skyrocketing popularity reshaping consumer expectations, this report is your roadmap to capturing market share in this $105 billion future.

Get the Report

Recommended Reports

Condition Specific

Sports Nutrition & Weight Management

Interested in more information?

Connect with us here.

This email was sent to you by the Informa Markets Division of Informa PLC (Privacy Policy).
Informa PLC's registered office is 5 Howick Place, London SW1P 1WG.
Registered in England and Wales. Number 8860726.

If you do not wish to receive further information from us, please click here.
Alternatively, to contact our data services team to have your details or preferences updated please email imdatateam@informa.com.